KPIs & Operating Metrics(New)
Growth Metrics

Gsk (GSK) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to $82.7 billion.

  • Gsk's Liabilities and Shareholders Equity rose 971.34% to $82.7 billion in Q3 2025 from the same period last year, while for Dec 2025 it was $238.3 billion, marking a year-over-year decrease of 2038.31%. This contributed to the annual value of $76.0 billion for FY2024, which is 356.76% up from last year.
  • Per Gsk's latest filing, its Liabilities and Shareholders Equity stood at $82.7 billion for Q3 2025, which was up 971.34% from $79.1 billion recorded in Q2 2025.
  • In the past 5 years, Gsk's Liabilities and Shareholders Equity ranged from a high of $112.1 billion in Q2 2022 and a low of $60.4 billion during Q1 2022
  • Over the past 5 years, Gsk's median Liabilities and Shareholders Equity value was $76.3 billion (recorded in 2024), while the average stood at $83.1 billion.
  • Per our database at Business Quant, Gsk's Liabilities and Shareholders Equity crashed by 4388.74% in 2022 and then skyrocketed by 1789.42% in 2023.
  • Over the past 5 years, Gsk's Liabilities and Shareholders Equity (Quarter) stood at $106.6 billion in 2021, then plummeted by 33.84% to $70.5 billion in 2022, then grew by 3.81% to $73.2 billion in 2023, then increased by 4.21% to $76.3 billion in 2024, then grew by 8.42% to $82.7 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $82.7 billion for Q3 2025, versus $79.1 billion for Q2 2025 and $76.5 billion for Q1 2025.